PE-22-28 8 mg – Spark of Neural Renewal
Spark Your Depression Research
Imagine a lab where mood lifts, neurons regenerate, and depression fades faster than ever. PE-22-28 8 mg from Peptide Sciences USA makes this real. This spadin-derived peptide inhibits TREK-1 channels, doubling neurogenesis and synaptogenesis in just 4 days, driving breakthroughs in depression and neuroprotection research. It's your spark for leading transformative studies, crafted for trailblazing researchers like you.
The Science Behind Neural Renewal
PE-22-28 (sequence: Gly-Val-Ser-Trp-Gly-Leu-Arg-OH) is a 7-amino-acid synthetic derivative of spadin, a sortilin-derived peptide that potently inhibits TREK-1 (KCNK2) potassium channels (IC50: 0.12 nM). By blocking TREK-1 in brain regions like the hippocampus and prefrontal cortex, it enhances neuronal excitability and serotonin signaling. In mouse models, PE-22-28 doubled BrdU-positive cells (neurogenesis marker) and synapse formation after 4 days, compared to 2–4 weeks for traditional antidepressants.
It also increases CREB, a transcription factor linked to memory and neuroplasticity, per [web:0,10]. PE-22-28's stability (up to 23 hours vs. spadin's 7 hours) makes it ideal for studying depression, stroke recovery, Alzheimer's, and neuroprotection. The 8 mg injectable dosage offers high bioavailability for rapid-onset research into mood regulation and neural repair.
Why PE-22-28 8 mg Fuels Your Studies
PE-22-28 isn't just a peptide—it's a spark that transforms depression research. Here's what makes it shine:
- Rapid Antidepressant Action: Reduces immobility in forced swim tests within 4 days.
- Neurogenesis Boost: Doubles BrdU-positive cells in the hippocampus.
- Synaptogenesis Support: Enhances synapse formation by 2x in preclinical models.
- Neuroprotection Potential: Protects against stroke and Alzheimer's pathology.
- Top Quality: Crafted by Peptide Sciences USA with 99% purity for reliable results.
With PE-22-28 8 mg, you're not just studying—you're leading a breakthrough in neural renewal and mental health.
Product Specifications
Peptide Sciences USA's PE-22-28 8 mg is your key to cutting-edge depression studies. Here's the breakdown:
- Composition: Contains 8 mg PE-22-28 (C35H55N11O9, ~797.9 g/mol).
- Pack Size: Single vial of lyophilized powder, requiring reconstitution for subcutaneous or intravenous injection.
- Manufacturing: Produced by Peptide Sciences USA with 99% purity, verified by HPLC and Mass Spectrometry, per [web:0,4].
- Usage Guidelines: Reconstitute with 1–2 mL bacteriostatic water (4–8 mg/mL). Inject 100–200 mcg (0.1–0.2 mg) subcutaneously or intravenously daily for 4–14 days in research protocols, per [web:7,11]. Use under professional supervision.
- Storage: Store lyophilized powder at -20°C for long-term stability or 4°C for short-term use (up to 3–4 weeks). After reconstitution, refrigerate at 2–8°C and use within 4–6 weeks.
- Safety: Preclinical studies report minimal side effects, with no significant TREK-1-related adverse effects; limited human data requires oversight.
This peptide is for research purposes only, driving discoveries in depression and neuroprotection.
Legal Disclaimer
PE-22-28 8 mg is supplied for research purposes only and is not FDA-approved for therapeutic use, per regulations as of 2025. It is banned by the World Anti-Doping Agency (WADA) for performance-enhancing use. It is not intended to diagnose, treat, cure, or prevent any condition. Consult a licensed professional before use. Peptide Sciences USA assumes no liability for misuse. All information is educational and based on preclinical research.
Frequently Asked Questions
What is PE-22-28 peptide?
PE-22-28 is a 7-amino-acid spadin derivative that inhibits TREK-1 channels, promoting neurogenesis and antidepressant effects.
What are the benefits of PE-22-28 in research?
It boosts neurogenesis, synaptogenesis, and mood, with potential in depression, stroke, and Alzheimer's studies.
How is PE-22-28 8 mg administered in research?
Mix the 8 mg vial with 1–2 mL bacteriostatic water. Inject 100–200 mcg subcutaneously or intravenously daily for 4–14 days.
What are the potential side effects of PE-22-28?
Preclinical studies report minimal side effects, with no significant TREK-1-related adverse effects; limited human data requires oversight.
How does PE-22-28 support depression treatment?
It inhibits TREK-1, enhancing serotonin signaling and neurogenesis, reducing depressive behaviors in 4 days.
